| Ticker | FULC |
|---|---|
| ISIN | US3596161097 |
| Sector | Tecnología |
| Mercado | NASDAQ |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including b...
Fulcrum Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.